{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:33:29Z","timestamp":1745307209953,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Appropriate monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with prophylactic antiemetics is important for cancer patients. This study was performed to validate the clinical practice of antiemetic use with carboplatin-based chemotherapy in lung cancer patients in the Hokushin region (Toyama, Ishikawa, Fukui, and Nagano prefectures), Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We surveyed retrospective data of newly diagnosed and registered lung cancer patients initially treated with carboplatin-based chemotherapy in 21 principal hospitals in the Hokushin region linked with health insurance claims data between 2016 and 2017.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1082 lung cancer patients (861 [79.6%] men, 221 [20.4%] women; median age 69.4\u00a0years [range, 33\u201389\u00a0years]). All patients received antiemetic therapy, with 613 (56.7%) and 469 patients (43.3%) receiving 5-hydroxytryptamine-3 receptor antagonist\/dexamethasone double regimen and 5-hydroxytryptamine-3 receptor antagonist\/dexamethasone\/neurokinin-1 receptor antagonist triple regimen, respectively. However, the rates of double regimen and use of palonosetron were higher in Toyama and Fukui prefectures. Thirty-nine patients (3.6%) changed from double to triple regimen, while 41 patients (3.8%) changed from triple to double regimen after the second cycle, but six of these returned to triple antiemetics in subsequent cycles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adherence to antiemetic guidelines in clinical practice was high in Hokushin region. However, rates of double and triple antiemetic regimens differed between the four prefectures. Simultaneous analysis of nationwide registry and insurance data was valuable for evaluating and comparing the differences in the status of antiemesis and management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02524-2","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T23:02:32Z","timestamp":1687820552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region"],"prefix":"10.1186","volume":"23","author":[{"given":"Takayuki","family":"Ide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoe","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-0960","authenticated-orcid":false,"given":"Tomonobu","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"2524_CR1","doi-asserted-by":"publisher","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol. 2021;26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3.","DOI":"10.1007\/s10147-020-01818-3"},{"key":"2524_CR2","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2017;35:3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614.","DOI":"10.1200\/JCO.2010.34.4614"},{"issue":"suppl 5","key":"2524_CR3","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdq194","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-133. https:\/\/doi.org\/10.1093\/annonc\/mdq194. PMID: 20555089.","journal-title":"Ann Oncol"},{"key":"2524_CR4","unstructured":"NCCN clinical practice guidelines in oncology Antiemesis Version 2.2017. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf (Accessed 2 Feb 2019)."},{"key":"2524_CR5","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/cncr.30054","volume":"122","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016;122:2418\u201325. https:\/\/doi.org\/10.1002\/cncr.30054.","journal-title":"Cancer"},{"key":"2524_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84:259\u201364. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.017.","journal-title":"Lung Cancer"},{"key":"2524_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21:491\u20137. https:\/\/doi.org\/10.1007\/s10147-015-0928-y.","journal-title":"Int J Clin Oncol"},{"key":"2524_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20:855\u201365. https:\/\/doi.org\/10.1007\/s10147-015-0786-7.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2524_CR9","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","volume":"25","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K, Tamura K. A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist. 2020;25(2):e373\u201380. https:\/\/doi.org\/10.1634\/theoncologist.2019-0292.","journal-title":"Oncologist"},{"key":"2524_CR10","doi-asserted-by":"publisher","unstructured":"Okuyama A, Boku N, Higashi T. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database. Cancer Rep Hoboken.2021;e1482. https:\/\/doi.org\/10.1002\/cnr2.1482.","DOI":"10.1002\/cnr2.1482"},{"key":"2524_CR11","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K. Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist. 2021;26:e1073\u201382. https:\/\/doi.org\/10.1002\/onco.13716.","journal-title":"Oncologist"},{"key":"2524_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00432-021-03620-8","volume":"148","author":"H Uramoto","year":"2022","unstructured":"Uramoto H, Takiguchi T, Koizumi T, Tanimoto A, Hayashi R, Nakazawa Y, et al. Multi-institutional survey of thymic carcinoma patients in Hokushin region. J Cancer Res Clin Oncol. 2022;148:419\u201324. https:\/\/doi.org\/10.1007\/s00432-021-03620-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2524_CR13","doi-asserted-by":"publisher","unstructured":"Sato S, Tanimoto A, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, et al. Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. Int J Clin Oncol.2021;26:1009\u20131014. https:\/\/doi.org\/10.1007\/s10147-021-01890-3","DOI":"10.1007\/s10147-021-01890-3"},{"key":"2524_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyab174","volume":"52","author":"E Okura","year":"2022","unstructured":"Okura E, Nishino Y, Sakashita K, Tanimoto A, Hayashi R, Yoshida Y, et al. Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. Jpn J Clin Oncol. 2022;52:86\u201395. https:\/\/doi.org\/10.1093\/jjco\/hyab174.","journal-title":"Jpn J Clin Oncol"},{"key":"2524_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2014;10:68\u201374. https:\/\/doi.org\/10.1200\/JOP.2012.000816.","journal-title":"J Oncol Pract"},{"key":"2524_CR16","doi-asserted-by":"publisher","unstructured":"Fujiwara S, Terai Y, Tsunetoh S, Sasaki H, Kanemura M, Ohmichi M. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. J Gynecol Oncol.2015; 26:311\u2013319. https:\/\/doi.org\/10.3802\/jgo.2015.26.4.311.","DOI":"10.3802\/jgo.2015.26.4.311"},{"key":"2524_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-021-00204-z","volume":"7","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Saito Y, Mitamura T, Takekuma Y, Sugawara M. Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. J Pharm Health Care Sci. 2021;7:21. https:\/\/doi.org\/10.1186\/s40780-021-00204-z.","journal-title":"J Pharm Health Care Sci"},{"key":"2524_CR18","doi-asserted-by":"publisher","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer.2015;90:410\u2013416. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.009.","DOI":"10.1016\/j.lungcan.2015.11.009"},{"key":"2524_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40360-018-0278-2","volume":"20","author":"N Yoshida","year":"2019","unstructured":"Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T, et al. Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacol Toxicol. 2019;20:6. https:\/\/doi.org\/10.1186\/s40360-018-0278-2.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2524_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(08)70313-9.","journal-title":"Lancet Oncol"},{"key":"2524_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12885-021-07802-y","volume":"21","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T, Egawa T. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21:74. https:\/\/doi.org\/10.1186\/s12885-021-07802-y.","journal-title":"BMC Cancer"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02524-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T23:02:39Z","timestamp":1687820559000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02524-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02524-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki Approval and approved by the Institutional Review Board of Shinshu University School of Medicine (No.5054) and institutional review board approval was obtained from each participating facility for creating the database. The dataset was used with permission from the Data Utilization Committee of Hokushin Ganpro Database Project (Institutional Review Board of Kanazawa University, No.2750\u20134). The need for informed consent was waived by the Institutional Review Boards of Shinshu University School of Medicine (No.5054) and Kanazawa University (No.2750\u20134) due to the retrospective nature of the study and handling anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors were supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan, under the Cancer Professional Training Plan to Meet Various Emerging Needs. The authors declare that they have no competing interest with respect to this research, authorship, and\/or publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}